Literature DB >> 17198036

Cardiovascular pharmacotherapy update for the intensive care unit.

James C Coons1, Edward Seidl.   

Abstract

Pharmacologic agents including vasodilators, inotropes, and vasopressors are frequently used in the critical care setting for management of the unstable cardiac patient. These medications are used to elicit varying effects on vascular resistance, myocardial contractility, and heart rate to help achieve desired hemodynamic and clinical endpoints. Therefore, it is important for the critical care nurse to have a practical understanding and working knowledge of cardiovascular pharmacotherapy in the intensive care unit setting. This article reviews the pharmacology and clinical utility of commonly used intravenous "vasoactive" medications encountered in the intensive care unit. We also highlight innovations in pharmacotherapy for this patient population, and provide practical considerations for the most appropriate and safe use of these medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198036     DOI: 10.1097/00002727-200701000-00006

Source DB:  PubMed          Journal:  Crit Care Nurs Q        ISSN: 0887-9303


  3 in total

1.  Controllable expansion of primary cardiomyocytes by reversible immortalization.

Authors:  Yue Zhang; Edem Nuglozeh; Fatouma Touré; Ann Marie Schmidt; Gordana Vunjak-Novakovic
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

2.  Immediate intravenous epinephrine versus early intravenous epinephrine for in-hospital cardiopulmonary arrest.

Authors:  Abdullah Bakhsh; Maha Safhi; Ashwaq Alghamdi; Amjad Alharazi; Bedoor Alshabibi; Rajwa Alobaidi; Maryam Alnashri
Journal:  BMC Anesthesiol       Date:  2021-05-13       Impact factor: 2.217

3.  Impact of Different Initial Epinephrine Treatment Time Points on the Early Postresuscitative Hemodynamic Status of Children With Traumatic Out-of-hospital Cardiac Arrest.

Authors:  Yan-Ren Lin; Yuan-Jhen Syue; Waradee Buddhakosai; Huai-En Lu; Chin-Fu Chang; Chih-Yu Chang; Cheng Hsu Chen; Wen-Liang Chen; Chao-Jui Li
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.